IKP celebrated 50th anniversary

From Bench to Bedside

-Personalized Medicine as Key to Targeted Therapy-

September 7, 2023 | Maritim Hotel Stuttgart

IKP | May 2023

Impressions

More Impressions in our

Gallery

Late 1973, the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP), Stuttgart, opened its doors and started operating with a number of staff of 4.
Originating from a generous donation by Dr. Margarete Fischer-Bosch, the eldest daughter of Robert Bosch, the institute has been growing over the past 50 years to an internationally highly recognized institution with major translational research activities in the field of pharmacogenomics and personalized medicine.

AdobeStock

Program

Welcome

14:00	Prof. Mark Dominik Alscher \| Bosch Health Campus
14:05	Dr. Christof Bosch \| Representative of the Bosch Family
14:10	Dr. Bernhard Straub \| Robert Bosch Foundation
14:15	Dr. Ute Leidig \| State Secret., Ministry for Social Affairs, Health & Integration, Baden-Wuerttemberg
14:20	Prof. Samuel Wagner \| Vice Dean for Digit. & Young Scientists, Med. Faculty of the Univ. Tuebingen

Moderation | Dr. Astrid Viciano, Medical Journalist

Opening Symposium

14:25

Prof. Matthias Schwab | Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology

Lectures

14:30	Prof. Dan Mark Roden \| Vanderbilt University, Medical Center, Nashville, USA
	Tools to probe variable drug actions: from pluripotent stem cells to electronic health records
14:55	Prof. Henk-Jan Guchelaar \| Leiden University Medical Center, Netherlands
	Pharmacogenomics: the time for implementation is now
15:20	Prof. Georg Schett \| Vice President Research, FAU, Med. Faculty, Intern. Med.III, Erlangen, Germany
	Car-T cell therapy in autoimmune disease
15:45	Coffee break
16:15	Prof. V. Craig Jordan \| University of Texas, MD Anderson Cancer Center, Houston, USA
	Tamoxifen from failed contraceptive to the first targeted therapy to treat breast cancer and an on-site into Selective Estrogen Receptor Modulators in women’s health
16:40	Prof. Juliane Walz \| University Hospital Tuebingen, Germany
	Peptide-based immunotherapy – bench to bedside development
17:05	Prof. Heyo Kroemer \| CEO Charité, University Medicine Berlin, Germany
	The Future of Health